Showing 1 - 10 of 133
Persistent link: https://www.econbiz.de/10009426456
Persistent link: https://www.econbiz.de/10001719206
Persistent link: https://www.econbiz.de/10013119195
Persistent link: https://www.econbiz.de/10013087678
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity. We ask how market size measured by condition...
Persistent link: https://www.econbiz.de/10013215338
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity. We ask how market size measured by condition...
Persistent link: https://www.econbiz.de/10012468948
Persistent link: https://www.econbiz.de/10013441894
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10003977959
I examine the effect of pharmaceutical innovation on the functional status of nursing home residents using cross-sectional, patient-level data from the 2004 National Nursing Home Survey. This was the first public-use survey of nursing homes that contains detailed information about medication...
Persistent link: https://www.econbiz.de/10013066848
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10013069689